BridgeBio Pharma, Inc. (BBIO)
Nasdaq: BBIO · Pharmaceutical Preparations · Palo Alto, CA · filing with the SEC since 2018
Who owns BridgeBio Pharma, Inc.
As filed with the SECHolders of 5% or more
5
Janus Henderson Group PLC holds 6.8% of Common Stock, as its SCHEDULE 13G/A filed May 15, 2026 says.
Directors and officers
16
report now, of 24 people on the record since 2019. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 5 named at left.
Holders of 5% or moreshare of the class, as filed
Janus Henderson Group PLC
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock · 5.7% in Feb 17, 2026
Farallon Capital Management, L.L.C.
SCHEDULE 13G/A · filed Aug 3, 2026 · Common Stock, par value $0.001 per share (the "Shares")
Dapice Joshua J.
SCHEDULE 13G · filed May 29, 2026 · Common Stock, par value $0.001 per share (the "Shares")
Blackrock, Inc.
SCHEDULE 13G · filed Oct 27, 2026 · Common Stock · 4.96% in Jul 27, 2026
Viking Global Investors LP
SCHEDULE 13D/A · filed Jul 10, 2026 · Common Stock, par value $0.001 per share · 6.1% in Apr 2, 2026
KKR Group Partnership L.P.
SCHEDULE 13D/A · filed Aug 17, 2026 · Common Stock, par value $0.001 per share · reported falling below 5%, from 7% in May 14, 2025
Neil Kumar
SCHEDULE 13G/A · filed Apr 16, 2026 · Common Stock, par value $0.001 per share · reported falling below 5%, from 5.41% in Feb 13, 2025
T. Rowe Price Associates, Inc.
SCHEDULE 13G · filed Nov 14, 2025 · COMMON STOCK · reported falling below 5%
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%, from 8.68% in Jul 29, 2025
What BBIO reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
BridgeBio Oncology Therapeutics, Inc.
An investee · investee · invested in, named in the 10-K filed Feb 24, 2026
Gondola Bio Llc
An investee · investee · invested in, named in the 10-K filed Feb 24, 2026
40 subsidiaries in 9 countries, from the list filed with the 10-K filed Feb 24, 2026.
Insider tradesForm 4
154sales
0purchases
148sales on a scheduled plan
9people selling
$105Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 3, 2025 to Nov 3, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 3, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window9 of 44 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Kumar Neil | Chief Executive Officer | 114 | $57.2M | 114 | 0 | $0 |
| Cook Jennifer E. | director | 6 | $21.9M | 6 | 0 | $0 |
| Lo Andrew | director | 4 | $6.3M | 0 | 0 | $0 |
| Ellis Andrea | director | 2 | $5.7M | 2 | 0 | $0 |
| Valantine Hannah | director | 6 | $4.4M | 5 | 0 | $0 |
| Daniels Ronald J | director | 1 | $3.9M | 0 | 0 | $0 |
| Trimarchi Thomas | President and CFO | 6 | $3.0M | 6 | 0 | $0 |
| Scott Randal W. | director | 9 | $2.1M | 9 | 0 | $0 |
| Apuli Maricel | Chief Accounting Officer | 6 | $800,000 | 6 | 0 | $0 |